Outcomes for COPD pharmacological trials: from lung function to biomarkers.

scientific article published on February 2008

Outcomes for COPD pharmacological trials: from lung function to biomarkers. is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1183/09031936.00099306
P698PubMed publication ID18238951
P5875ResearchGate publication ID5612896

P50authorClive PageQ29643391
William MacNeeQ38326286
Marc MiravitllesQ40059112
American Thoracic SocietyQ467061
P2093author name stringP J Barnes
M Cazzola
V Brusasco
P W Jones
E F Wouters
M P Rutten-van Mölken
S D Sullivan
D A Mahler
K F Rabe
P S Burge
P Palange
S I Rennard
J A Wedzicha
P M A Calverley
F J Martinez
R Stockley
B Make
M Pistolesi
B R Celli
D Parr
European Respiratory Society Task Force on outcomes of COPD
L G Franciosi
P433issue2
P921main subjectpharmacologyQ128406
biomarkerQ864574
P304page(s)416-469
P577publication date2008-02-01
P1433published inEuropean Respiratory JournalQ12257435
P1476titleOutcomes for COPD pharmacological trials: from lung function to biomarkers
P478volume31

Reverse relations

cites work (P2860)
Q89939209A Nomogram for Predicting Severe Exacerbations in Stable COPD Patients
Q35230811A bibliometric analysis of the 100 most influential papers on COPD
Q44494841A model-based longitudinal meta-analysis of FEV1 in randomized COPD trials
Q30578043A pilot survey on the quality of life in respiratory rehabilitation carried out in COPD patients with severe respiratory failure: preliminary data of a novel Inpatient Respiratory Rehabilitation Questionnaire (IRRQ)
Q36278452A pragmatic cluster randomized controlled trial of early intervention for chronic obstructive pulmonary disease by practice nurse-general practitioner teams: Study Protocol
Q62825758A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD
Q36907994A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD
Q26992071A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges
Q38308369A review on airway biomarkers: exposure, effect and susceptibility.
Q43418314ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients
Q64087842Acceptance, adherence and dropout rates of individuals with COPD approached in telehealth interventions: a protocol for systematic review and meta-analysis
Q38066977Aclidinium bromide for the treatment of chronic obstructive pulmonary disease
Q43695468Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease
Q38112092Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease
Q35191130Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial
Q87418827Aclidinium: in chronic obstructive pulmonary disease
Q34521884Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
Q37822219Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine
Q48009363Adequate continuous positive airway pressure therapy reduces mortality in Chinese patients with obstructive sleep apnea
Q35046919Admission prevention in COPD: non-pharmacological management
Q38797163Advances in Identifying Urine/Serum Biomarkers in Alpha-1 Antitrypsin Deficiency for More Personalized Future Treatment Strategies
Q26772710Aeroparticles, Composition, and Lung Diseases
Q23912608Agricultural work exposures and pulmonary function among hired farm workers in California (the MICASA study)
Q38937853An ECLIPSE View of Alpha-1 Antitrypsin Deficiency
Q37808058An update on the use of indacaterol in patients with COPD.
Q33755801Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life
Q37734436Arformoterol tartrate in the treatment of COPD.
Q38038596Assessment of COPD wellness tools for use in primary care: an IPCRG initiative
Q37287138Assessment of patients with chronic obstructive pulmonary disease
Q47334748Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography.
Q34432556Association between lung function and exacerbation frequency in patients with COPD.
Q36412702Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients
Q36408615Asthma symptom utility index: reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients
Q24197535Beclometasone for chronic obstructive pulmonary disease
Q38055149Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement
Q37973657Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes
Q47677150Bioequivalence of a Liquid Formulation of Alpha1-Proteinase Inhibitor Compared with Prolastin®-C (Lyophilized Alpha1-PI) in Alpha1-Antitrypsin Deficiency
Q40398456Biologic lung volume reduction in advanced upper lobe emphysema: phase 2 results
Q45720028Biomarkers in COPD: is mortality the Holy Grail?
Q37937720Biomarkers of therapeutic response in patients with chronic obstructive pulmonary disease: a critical review of the literature
Q37012728Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease
Q38109057Blood specimen biomarkers of inflammation, matrix degradation, angiogenesis, and cardiac involvement: a future useful tool in assessing clinical outcomes of COPD patients in clinical practice?
Q36027413Bronchoabsorption; a novel bronchoscopic technique to improve biomarker sampling of the airway.
Q34049219Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data
Q38939466Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD.
Q38946604Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease
Q42943788Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD
Q84112341C reactive protein and alpha1-antitrypsin: relationship between levels and gene variants
Q35637295COPD association and repeatability of blood biomarkers in the ECLIPSE cohort
Q38154256COPD management: role of symptom assessment in routine clinical practice.
Q36964961COPD: what is the unmet need?
Q26766294Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs
Q30388877Changes in cystic fibrosis airway microbial community associated with a severe decline in lung function
Q34554816Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease
Q37323319Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.
Q41815663Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches
Q38838404Chinese Herbal Medicine and Salmeterol and Fluticasone Propionate for Chronic Obstructive Pulmonary Disease: Systematic Review and Network Meta-Analysis
Q34073318Chinese herbal medicine (weijing decoction) combined with pharmacotherapy for the treatment of acute exacerbations of chronic obstructive pulmonary disease
Q38065457Chronic bronchial infection in COPD. Is there an infective phenotype?
Q26801134Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life
Q34658113Clinical value of forced expiratory volume in 1 s (FEV1) in chronic obstructive pulmonary disease
Q34500895Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD.
Q24235761Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
Q26471530Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
Q24200446Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease
Q57817177Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
Q39399389Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis
Q37490124Comparison of arterial and venous blood biomarker levels in chronic obstructive pulmonary disease
Q97530192Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Q36385615Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression
Q37930206Controversies in treatment of chronic obstructive pulmonary disease
Q36384150Correlations between disease-specific and generic health status questionnaires in patients with advanced COPD: a one-year observational study
Q37992679Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues
Q36258855Cost-effectiveness of integrated COPD care: the RECODE cluster randomised trial
Q33991002Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores
Q38261881Dang shen [Codonopsis pilosula (Franch.) Nannf] herbal formulae for chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Q38068885Deciding what type of evidence and outcomes to include in guidelines: article 5 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report
Q92665731Decline of COPD exacerbations in clinical trials over two decades - a systematic review and meta-regression
Q37610458Defining disease modification in chronic obstructive pulmonary disease
Q38503383Defining exacerbations in chronic obstructive pulmonary disease
Q38208244Defining phenotypes in COPD: an aid to personalized healthcare.
Q43897461Demographic and clinical characteristics associated with quality of life in patients with chronic obstructive pulmonary disease
Q35216364Depression and heart failure associated with clinical COPD questionnaire outcome in primary care COPD patients: a cross-sectional study.
Q91788881Development and Validation of the Modified Patient-Reported Outcome Scale for Chronic Obstructive Pulmonary Disease (mCOPD-PRO)
Q57035370Development of a core outcome set for trials investigating the long-term management of bronchiectasis
Q37099911Development of the chronic obstructive pulmonary disease morning symptom diary (COPD-MSD)
Q26751313Diagnosing COPD: advances in training and practice - a systematic review
Q35956386Diffusion-weighted hyperpolarized 129Xe MRI in healthy volunteers and subjects with chronic obstructive pulmonary disease
Q52679681Disease Management Plus Recommended Care versus Recommended Care Alone for Ambulatory COPD Patients.
Q53062786Disease severity and symptoms among patients receiving monotherapy for COPD.
Q54985483Distinct pain profiles in patients with chronic obstructive pulmonary disease.
Q64229239Distinct skeletal muscle molecular responses to pulmonary rehabilitation in chronic obstructive pulmonary disease: a cluster analysis
Q38091512Do we know the minimal clinically important difference (MCID) for COPD exacerbations?
Q94512346Does the 6-minute walk test in hospitalized COPD patients exclusively correlate with lung function parameters or should psychological factors also be taken into account?
Q35170142Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD.
Q55430075Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).
Q37228266Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
Q51677873Drug development for chronic lung disease--mission impossible?
Q30249747Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis
Q42384700Dual bronchodilation and exacerbations of COPD.
Q26752988Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
Q36223222Dyspnea, depression and health related quality of life in pulmonary arterial hypertension patients
Q39677216E pluribus plurima: multidimensional indices and clinical phenotypes in COPD
Q36636050Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations
Q50033239Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
Q55485805Effect of Liuzijue Exercise Combined with Elastic Band Resistance Exercise on Patients with COPD: A Randomized Controlled Trial.
Q90729065Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels and Quality of Life at One Year
Q24635347Effect of doxycycline in patients of moderate to severe chronic obstructive pulmonary disease with stable symptoms
Q34198955Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis
Q94553029Effect of procalcitonin on the prognosis of patients with COPD
Q64079595Effectiveness and Safety of Oral on Stable COPD of GOLD Stages 2-3: Systematic Review and Meta-Analysis
Q47879585Effectiveness of a Respiratory Day Hospital Program to Reduce Admissions for Exacerbation in Patients with Severe COPD: A Prospective, Multicenter Study
Q34033143Effectiveness of the Assessment of Burden of Chronic Obstructive Pulmonary Disease (ABC) tool: study protocol of a cluster randomised trial in primary and secondary care
Q36704580Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.
Q64245613Effects of Different Comorbidities on Health-Related Quality of Life among Respiratory Patients in Vietnam
Q35766357Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease
Q37785279Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease
Q37110198Efficacy and Safety of Roflumilast in Korean Patients with COPD.
Q38604641Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study
Q35686996Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial
Q48485039Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
Q37209291Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study
Q46576729Efficacy and safety of bronchoscopic lung volume reduction therapy in patients with severe emphysema: a meta-analysis of randomized controlled trials
Q21257191Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study
Q54467741Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
Q34995066Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
Q44756130Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial.
Q38604621Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily Activities
Q34316776Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis
Q37555782Efficacy of tiotropium in the prevention of exacerbations of COPD.
Q28075367Efficacy of tiotropium-olodaterol fixed-dose combination in COPD
Q36526988Eight-step method to build the clinical content of an evidence-based care pathway: the case for COPD exacerbation
Q54963373Emerging Evidence of Thresholds for Beneficial Effects from Vitamin D Supplementation.
Q28383300Emphysema predicts hospitalisation and incident airflow obstruction among older smokers: a prospective cohort study
Q39435739Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study.
Q34940755Endogenous testosterone level and testosterone supplementation therapy in chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis.
Q51599981Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives.
Q34984451Evaluation of correlation of BODE index with health-related quality of life among patients with stable COPD attending a tertiary care hospital
Q33554553Evaluation of malnutrition detected with the Nutritional Risk Screening 2002 (NRS-2002) and the quality of life in hospitalized patients with chronic obstructive pulmonary disease
Q39627403Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies
Q30949429Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data.
Q26745663Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease
Q37862607Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations.
Q58579811Flow and volume response to bronchodilator in patients with COPD
Q93184812Forced expiratory volumes in 3 s is a sensitive clinical measure for assessment of bronchodilator reversibility in elderly Chinese with severe lung function impairment
Q37416866From large clinical trials to management of COPD in the real world
Q33509146From proteomics to prescription-the search for COPD biomarkers
Q51559494Functional respiratory imaging (FRI) for optimizing therapy development and patient care.
Q35936008Gaps in using bronchodilators, inhaled corticosteroids and influenza vaccine among 23 high- and low-income sites
Q38081908Growing awareness of the importance of health literacy in individuals with COPD.
Q34445946Health effects of the Federal Bureau of Prisons tobacco ban.
Q92331842Health-related quality of life of patients diagnosed with COPD in Extremadura, Spain: results from an observational study
Q89964040Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease
Q45803920Impact and prevention of severe exacerbations of COPD: a review of the evidence
Q38655574Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
Q34511113Improving communication between the physician and the COPD patient: an evaluation of the utility of the COPD Assessment Test in primary care
Q26851664Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol
Q38072277Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective
Q34962838Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis
Q48059168Indacaterol for the treatment of chronic obstructive pulmonary disease
Q34243574Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.
Q37778736Indacaterol: a new once daily long-acting beta2 adrenoceptor agonist
Q37987211Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease
Q57117321Influence of air pressure, humidity, solar radiation, temperature, and wind speed on ambulatory visits due to chronic obstructive pulmonary disease in Bavaria, Germany
Q38153757Inhaled corticosteroids for chronic obstructive pulmonary disease
Q34888769Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis
Q47661714Inhaled therapies in patients with moderate COPD in clinical practice: current thinking.
Q37199668Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies
Q47907472Integrated multidisciplinary community service for chronic obstructive pulmonary disease reduces hospitalisations
Q37622935Is there a role for antiinflammatory treatment in COPD?
Q30581769Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts
Q24194044Long-acting beta 2 -agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease
Q24197853Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis
Q38388302Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease
Q38646619Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: a systematic review and meta-analysis
Q39548676Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease.
Q61800223Longitudinal change of FEV 1 and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD
Q46075418Longitudinal changes in patient-reported dyspnea in patients with COPD.
Q45392088Longitudinal lung volume changes in patients with chronic obstructive pulmonary disease
Q94355405Long‐acting beta‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease
Q64319638Low income as a determinant of exercise capacity in COPD
Q35994827Lung development and the host response to influenza A virus are altered by different doses of neonatal oxygen in mice
Q34206825Lung function decline in relation to diagnostic criteria for airflow obstruction in respiratory symptomatic subjects
Q37168317Markers of early disease and prognosis in COPD.
Q35672964Measurement of C-reactive protein, procalcitonin and neutrophil elastase in saliva of COPD patients and healthy controls: correlation to self-reported wellbeing parameters
Q38175163Minimal clinically important differences in pharmacological trials
Q37421246Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study
Q51717909Minimum clinically important difference in diffusing capacity of the lungs for carbon monoxide among patients with severe and very severe chronic obstructive pulmonary disease.
Q31130295Multifractal analysis for nutritional assessment
Q87646805N-acetylcysteine for COPD: the evidence remains inconclusive--authors' reply
Q26768289N-acetylcysteine in COPD: why, how, and when?
Q37220006N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPD
Q41838638Natural histories of chronic obstructive pulmonary disease
Q38059466Nebulized arformoterol: what is its place in the management of COPD?
Q34768711Neuromuscular electrical stimulation improves exercise tolerance in chronic obstructive pulmonary disease patients with better preserved fat-free mass
Q37390883New developments in the management of COPD: clinical utility of indacaterol 75 μg.
Q37589154New drugs for exacerbations of chronic obstructive pulmonary disease
Q38083537No room to breathe: the importance of lung hyperinflation in COPD.
Q94571769Objective secondhand smoke exposure in chronic obstructive pulmonary disease patients without active smoking: the U.S. National Health and Nutrition Examination Survey (NHANES) 2007-2012
Q92156772Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
Q94347856Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
Q41844550Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial
Q47192702Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
Q36196805Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
Q42170464Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium
Q27010444Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy
Q34154974Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect
Q38477843Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study
Q45560084Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
Q30480535Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations
Q38633304Oxidation pathway and exacerbations in COPD: the role of NAC.
Q36485759Patient's perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL Study
Q45757076Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe
Q34519035Patient-reported dyspnea in COPD reliability and association with stage of disease
Q36275067Patterns and characterization of COPD exacerbations using real-time data collection
Q33706037Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities
Q92703042Pharmacogenomics of chronic obstructive pulmonary disease
Q89122759Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis
Q38817813Pharmacological management of breathlessness in COPD: recent advances and hopes for the future
Q28070274Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review
Q37924598Pharmacological treatment of COPD.
Q36254441Pharmacological treatment response according to the severity of symptoms in patients with chronic obstructive pulmonary disease
Q64097299Plasma cathelicidin and longitudinal lung function in current and former smokers
Q43297227Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide.
Q35111729Predictors of ICS/LABA prescribing in COPD patients: a study from general practice
Q37392322Prevalence of alpha-1 antitrypsin deficiency and allele frequency in patients with COPD in Brazil
Q37896372Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease
Q40786706Prognostic assessment in COPD without lung function: the B-AE-D indices.
Q36048443Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD.
Q34948185Proteomic differences with and without ozone-exposure in a smoking-induced emphysema lung model
Q38154291Pulmonary biomarkers in COPD exacerbations: a systematic review
Q92119093Pulmonary function decreases moderately after accelerated high-dose irradiation for stage III non-small cell lung cancer
Q34798279Putting health status guided COPD management to the test: protocol of the MARCH study.
Q38194114QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease
Q46271491Quality indicators for in-hospital management of exacerbation of chronic obstructive pulmonary disease: results of an international Delphi study
Q36759415Quantitative analysis of hyperpolarized 129Xe ventilation imaging in healthy volunteers and subjects with chronic obstructive pulmonary disease
Q34632774RECODE: design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care
Q35011666Radiological correlates and clinical implications of the paradoxical lung function response to β₂ agonists: an observational study
Q39758240Regional lung response to bronchodilator reversibility testing determined by electrical impedance tomography in chronic obstructive pulmonary disease.
Q35751737Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease
Q28484224Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum
Q36284259Reproducibility of optical coherence tomography airway imaging
Q33715834Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease.
Q38137141Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.
Q33824534Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials
Q37681577Roflumilast in chronic obstructive pulmonary disease: evidence from large trials
Q38730318Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease
Q37303247Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency.
Q35822151Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients
Q91566045Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine
Q41400534Saving Time for Patients with Moderate to Severe COPD: Endurance Test Speed Set Using Usual and Fast Walk Speeds.
Q37589149Screening for and early detection of chronic obstructive pulmonary disease
Q35042489Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease
Q38604595Socioeconomic Status as a Determinant of Health Status Treatment Response in COPD Trials
Q37168340Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations
Q58840506Systemic Effects of COPD: Just the Tip of the Iceberg
Q37765755Systemic corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease
Q38056532Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease
Q58718347Telehealth for patients with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis protocol
Q55154201Telerehabilitation versus traditional centre-based pulmonary rehabilitation for people with chronic respiratory disease: protocol for a randomised controlled trial.
Q47962475The Challenges of Precision Medicine in COPD.
Q37389639The Effect of Fatigue and Fatigue Intensity on Exercise Tolerance in Moderate COPD.
Q37248009The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension
Q26828971The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease
Q33817770The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients
Q37698333The clinical chronic obstructive pulmonary disease questionnaire: cut point for GOLD 2013 classification.
Q36982645The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease
Q38832398The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease
Q36308010The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
Q36300138The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases
Q37930205The future of chronic obstructive pulmonary disease treatment--difficulties of and barriers to drug development
Q41908094The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients
Q64101434The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
Q38052955The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease
Q91878017The prognostic values of neutrophil to lymphocyte ratio for outcomes in chronic obstructive pulmonary disease
Q36438669The role of bronchodilator treatment in the prevention of exacerbations of COPD.
Q38095144The role of desmosines as biomarkers for chronic obstructive pulmonary disease
Q38077797The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease
Q22305858The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease
Q34779478Three-month treatment response and exacerbation in chronic obstructive pulmonary disease.
Q26780553Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma
Q24194833Tiotropium versus placebo for chronic obstructive pulmonary disease
Q24202175Tiotropium versus placebo for chronic obstructive pulmonary disease
Q37419691Trachea epithelium as a "canary" for cigarette smoking-induced biologic phenotype of the small airway epithelium
Q39642495Transition of patients with COPD across different care settings: challenges and opportunities for hospitalists
Q38060087Treating the small airways
Q48710242Treatment of advanced emphysema with emphysematous lung sealant (AeriSeal®).
Q42260506Triple Therapy for Moderate-to-Severe Chronic Obstructive Pulmonary Disease.
Q37868010Triple therapy for the management of COPD: a review
Q42920605Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
Q54264691Tuberculosis and lung damage: from epidemiology to pathophysiology.
Q38248438Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.
Q37422824Update in chronic obstructive pulmonary disease 2008.
Q38241442Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease
Q87695799Updates in Chronic Obstructive Pulmonary Disease for the Year 2014
Q37944316Utility estimation in chronic obstructive pulmonary disease: a preference for change?
Q35710238V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results
Q33824230Validation and development of an immunonephelometric assay for the determination of alpha-1 antitrypsin levels in dried blood spots from patients with COPD.
Q91950215Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease
Q51066326Validity of a Self-administered Questionnaire Version of the Transition Dyspnea Index in Patients with COPD.
Q39219255Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial
Q36718728Warm homes for older people: aims and methods of a randomised community-based trial for people with COPD
Q35945635Which field walking test should be used to assess functional exercise capacity in lung cancer? An observational study
Q49047172Why doesn't reducing exacerbations decrease COPD mortality?
Q83445498[Patient-reported parameters in chronic obstructive pulmonary disease]
Q82954791[Pelargonium sidoides in acute bronchitis - Health-related quality of life and patient-reported outcome in adults receiving EPs 7630 treatment]
Q79690690[Should we screen for COPD in the population]

Search more.